170 related articles for article (PubMed ID: 33167335)
1. ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study).
Fleury H; Caldato S; Recordon-Pinson P; Thebault P; Guidicelli GL; Hessamfar M; Morlat P; Bonnet F; Visentin J
Viruses; 2020 Nov; 12(11):. PubMed ID: 33167335
[TBL] [Abstract][Full Text] [Related]
2. Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles.
Tumiotto C; Alves BM; Recordon-Pinson P; Jourdain M; Bellecave P; Guidicelli GL; Visentin J; Bonnet F; Hessamfar M; Neau D; Sanchez J; Brander C; Sajadi M; Eyzaguirre L; Soares EA; Routy JP; Soares MA; Fleury H
PLoS One; 2019; 14(2):e0212347. PubMed ID: 30811489
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive screening for human immunodeficiency virus type 1 subtype-specific CD8 cytotoxic T lymphocytes and definition of degenerate epitopes restricted by HLA-A0207 and -C(W)0304 alleles.
Currier JR; deSouza M; Chanbancherd P; Bernstein W; Birx DL; Cox JH
J Virol; 2002 May; 76(10):4971-86. PubMed ID: 11967314
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of HIV-1 CTL epitopes recognized by HLA I alleles in HIV-infected individuals at times near primary infection: the Provir/Latitude45 study.
Papuchon J; Pinson P; Guidicelli GL; Bellecave P; Thomas R; LeBlanc R; Reigadas S; Taupin JL; Baril JG; Routy JP; Wainberg M; Fleury H;
PLoS One; 2014; 9(6):e100452. PubMed ID: 24964202
[TBL] [Abstract][Full Text] [Related]
5. Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection.
Ojwach DBA; MacMillan D; Reddy T; Novitsky V; Brumme ZL; Brockman MA; Ndung'u T; Mann JK
J Virol; 2018 Oct; 92(19):. PubMed ID: 29997209
[TBL] [Abstract][Full Text] [Related]
6. Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele.
Ferrari G; Neal W; Ottinger J; Jones AM; Edwards BH; Goepfert P; Betts MR; Koup RA; Buchbinder S; McElrath MJ; Tartaglia J; Weinhold KJ
J Immunol; 2004 Aug; 173(3):2126-33. PubMed ID: 15265949
[TBL] [Abstract][Full Text] [Related]
7. Broad and cross-clade CD4+ T-cell responses elicited by a DNA vaccine encoding highly conserved and promiscuous HIV-1 M-group consensus peptides.
Almeida RR; Rosa DS; Ribeiro SP; Santana VC; Kallás EG; Sidney J; Sette A; Kalil J; Cunha-Neto E
PLoS One; 2012; 7(9):e45267. PubMed ID: 23028895
[TBL] [Abstract][Full Text] [Related]
8. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
[TBL] [Abstract][Full Text] [Related]
9. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.
Gahery H; Daniel N; Charmeteau B; Ourth L; Jackson A; Andrieu M; Choppin J; Salmon D; Pialoux G; Guillet JG
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):684-94. PubMed ID: 16831093
[TBL] [Abstract][Full Text] [Related]
10. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.
Kiepiela P; Leslie AJ; Honeyborne I; Ramduth D; Thobakgale C; Chetty S; Rathnavalu P; Moore C; Pfafferott KJ; Hilton L; Zimbwa P; Moore S; Allen T; Brander C; Addo MM; Altfeld M; James I; Mallal S; Bunce M; Barber LD; Szinger J; Day C; Klenerman P; Mullins J; Korber B; Coovadia HM; Walker BD; Goulder PJ
Nature; 2004 Dec; 432(7018):769-75. PubMed ID: 15592417
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes.
Garcia-Bates TM; Palma ML; Anderko RR; Hsu DC; Ananworanich J; Korber BT; Gaiha GD; Phanuphak N; Thomas R; Tovanabutra S; Walker BD; Mellors JW; Piazza PA; Kroon E; Riddler SA; Michael NL; Rinaldo CR; Mailliard RB;
EBioMedicine; 2021 Jan; 63():103175. PubMed ID: 33450518
[TBL] [Abstract][Full Text] [Related]
12. Screening for CD8 cytotoxic T lymphocytes specific for Gag of human immunodeficiency virus type 1 subtype B' Henan isolate from China and identification of novel epitopes restricted by the HLA-A2 and HLA-A11 alleles.
Gong X; Gui X; Zhang Y; Tien P
J Gen Virol; 2006 Jan; 87(Pt 1):151-158. PubMed ID: 16361427
[TBL] [Abstract][Full Text] [Related]
13. HLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703.
Matthews PC; Adland E; Listgarten J; Leslie A; Mkhwanazi N; Carlson JM; Harndahl M; Stryhn A; Payne RP; Ogwu A; Huang KH; Frater J; Paioni P; Kloverpris H; Jooste P; Goedhals D; van Vuuren C; Steyn D; Riddell L; Chen F; Luzzi G; Balachandran T; Ndung'u T; Buus S; Carrington M; Shapiro R; Heckerman D; Goulder PJ
J Immunol; 2011 May; 186(10):5675-86. PubMed ID: 21498667
[TBL] [Abstract][Full Text] [Related]
14. Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection.
Karlsson I; Brandt L; Vinner L; Kromann I; Andreasen LV; Andersen P; Gerstoft J; Kronborg G; Fomsgaard A
Clin Immunol; 2013 Feb; 146(2):120-30. PubMed ID: 23314272
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Vaccine Against HIV, Viral Variability, Cytotoxic T Lymphocyte Epitopes, and Genetics of Patients.
Fleury H; Tumiotto C; Bellecave P; Recordon-Pinson P
AIDS Res Hum Retroviruses; 2018 Jan; 34(1):27-30. PubMed ID: 28899104
[TBL] [Abstract][Full Text] [Related]
16. Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines.
Ferrari G; Kostyu DD; Cox J; Dawson DV; Flores J; Weinhold KJ; Osmanov S
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1433-43. PubMed ID: 11018863
[TBL] [Abstract][Full Text] [Related]
17. Identification of HLA-A*3101-restricted cytotoxic T-lymphocyte response to human immunodeficiency virus type 1 (HIV-1) in patients with chronic HIV-1 infection.
Borghan MA; Oka S; Takiguchi M
Tissue Antigens; 2005 Oct; 66(4):305-13. PubMed ID: 16185326
[TBL] [Abstract][Full Text] [Related]
18. HLA-DR-restricted peptides identified in the Nef protein can induce HIV type 1-specific IL-2/IFN-gamma-secreting CD4+ and CD4+ /CD8+ T cells in humans after lipopeptide vaccination.
Gahery H; Figueiredo S; Texier C; Pouvelle-Moratille S; Ourth L; Igea C; Surenaud M; Guillet JG; Maillere B
AIDS Res Hum Retroviruses; 2007 Mar; 23(3):427-37. PubMed ID: 17411376
[TBL] [Abstract][Full Text] [Related]
19. CD8
Murakoshi H; Zou C; Kuse N; Akahoshi T; Chikata T; Gatanaga H; Oka S; Hanke T; Takiguchi M
Retrovirology; 2018 Jul; 15(1):46. PubMed ID: 29970102
[TBL] [Abstract][Full Text] [Related]
20. Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines.
Borthwick N; Lin Z; Akahoshi T; Llano A; Silva-Arrieta S; Ahmed T; Dorrell L; Brander C; Murakoshi H; Takiguchi M; Hanke T
PLoS One; 2017; 12(4):e0176418. PubMed ID: 28448594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
